A clinical trial of mithramycin in the treatment of advanced malignant disease.
作者信息
Baum M
出版信息
Br J Cancer. 1968 Jun;22(2):176-83. doi: 10.1038/bjc.1968.25.
Abstract
摘要
相似文献
1
A clinical trial of mithramycin in the treatment of advanced malignant disease.光辉霉素治疗晚期恶性疾病的临床试验。
Br J Cancer. 1968 Jun;22(2):176-83. doi: 10.1038/bjc.1968.25.
2
Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.吡唑呋喃对晚期结直肠癌患者的II期评估。
Cancer Treat Rep. 1979 Jan;63(1):139-40.
3
[Results of clinical study of the antineoplastic antibiotic rubomycin].[抗肿瘤抗生素柔红霉素的临床研究结果]
Antibiotiki. 1968 Sep;13(9):846-50.
4
Phase II study of pyrazofurin in advanced colorectal carcinoma.吡唑呋喃用于晚期结直肠癌的II期研究。
Cancer Treat Rep. 1977 May-Jun;61(3):491-3.
5
Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.阿西维辛治疗晚期乳腺癌的II期试验：一项癌症与白血病B组研究
Cancer Treat Rep. 1986 Oct;70(10):1247-8.
6
Phase II trial of esorubicin in patients with advanced colorectal carcinoma.表柔比星用于晚期结直肠癌患者的II期试验。
Cancer Treat Rep. 1986 Oct;70(10):1241-2.
7
Hypercalcemic crisis in neoplastic diseases: management with mithramycin.肿瘤性疾病中的高钙血症危象：光神霉素治疗
Surgery. 1972 Apr;71(4):631-5.
8
Clinical trials with adriamycin.阿霉素的临床试验。
Cancer. 1971 Oct;28(4):844-50. doi: 10.1002/1097-0142(1971)28:4<844::aid-cncr2820280407>3.0.co;2-9.
9
Mithramycin therapy in advanced testicular neoplasms.光辉霉素治疗晚期睾丸肿瘤
Cancer. 1970 Oct;26(4):755-66. doi: 10.1002/1097-0142(197010)26:4<755::aid-cncr2820260403>3.0.co;2-u.
10
A trial of streptonigrin in the treatment of advanced malignant disease.一项关于链黑菌素治疗晚期恶性疾病的试验。
Br J Cancer. 1967 Jun;21(2):295-301. doi: 10.1038/bjc.1967.32.
引用本文的文献
1
The Hypomethylating Agent 5-Azacitidine Potentiates the Effect of RAS and Sp1 Inhibitors in Neuroblastoma Cells.低甲基化剂5-氮杂胞苷增强RAS和Sp1抑制剂对神经母细胞瘤细胞的作用。
Acta Naturae. 2025 Apr-Jun;17(2):86-97. doi: 10.32607/actanaturae.27558.
2
Integrative analysis of transcriptome, DNA methylome, and chromatin accessibility reveals candidate therapeutic targets in hypertrophic cardiomyopathy.转录组、DNA 甲基化组和染色质可及性的综合分析揭示了肥厚型心肌病的候选治疗靶点。
Protein Cell. 2024 Nov 1;15(11):796-817. doi: 10.1093/procel/pwae032.
3
Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.依维莫司和plicamycin 特异性靶向 CMS4 亚型的化疗耐药结直肠癌细胞。
Cell Death Dis. 2021 Oct 21;12(11):978. doi: 10.1038/s41419-021-04270-x.
4
Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.用于克服卵巢癌顺铂耐药性的光神霉素及其类似物
Biomedicines. 2021 Jan 12;9(1):70. doi: 10.3390/biomedicines9010070.
5
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.米托蒽醌治疗导致肝细胞胆汁转运蛋白表达改变引起的严重肝毒性。
Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7.
6
Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage.米托蒽醌 A 增强肿瘤对 DNA 损伤导致的有丝分裂灾难的敏感性。
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):344-352. doi: 10.1016/j.ijrobp.2017.09.049. Epub 2017 Oct 12.
7
Letter: Renal function and electrolyte disturbances in normocalcaemic and hypercalcaemic patients treated with mithramycin.信函：用光辉霉素治疗的血钙正常和高钙血症患者的肾功能及电解质紊乱
Br J Cancer. 1974 Jun;29(6):490-1. doi: 10.1038/bjc.1974.103.
本文引用的文献
1
SERUM ENZYME ACTIVITY DURING RADIOTHERAPY OF MALIGNANT TUMOURS.恶性肿瘤放疗期间的血清酶活性
Br J Cancer. 1965 Mar;19(1):134-8. doi: 10.1038/bjc.1965.15.
2
Clinical trial with mithramycin.
Cancer Chemother Rep. 1963 May;29:109-10.
3
Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease.光辉霉素对恶性疾病患者钙和羟脯氨酸代谢的影响。
Br Med J. 1967 Feb 25;1(5538):474-7. doi: 10.1136/bmj.1.5538.474.
4
A trial of mithramycin in the treatment of advanced malignant disease.光辉霉素治疗晚期恶性疾病的试验。
Br J Cancer. 1966 Jun;20(2):256-63. doi: 10.1038/bjc.1966.32.
Zotero 插件